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Background: Recent studies have found that periostin (PN), as a kind of secreted glycoprotein, is closely related to
the metastatic potential and prognosis of many kinds of tumors. This study aimed to examine the expression of PN
in patients with osteosarcoma and explore the relationship of PN expression with clinicopathologic factors and
prognosis.
Methods: PN was detected by histopathological and immunohistochemical methods in 62 cases of osteosarcoma
and 62 of osteochondroma. Detailed pathological and clinical data were collected by reviewing medical records.
Results: The results showed that increased PN protein expression was prevalent in osteosarcoma and was
significantly associated with pathologic subtype (P =0.000), tumor size (P =0.016) and Enneking stage (P =0.047).
Additionally, expression of PN was found to be an independent prognostic factor in osteosarcoma patients. High
expression of PN protein is closely correlated to the tumor progression and poor survival of osteosarcoma.
Conclusions: Our data suggest that PN is a promising biomarker for identifying individuals with poor prognostic
potential and suggests its possible use as a prognostic marker in patients with osteosarcoma.
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Osteosarcoma accounts for approximately 20% of pri-
mary malignancies of bone, which is the most common
malignant primary bone tumor among children and ado-
lescents [1]. It frequently tends to develop distant metas-
tasis and ultimately results in death, especially in cases
of lung metastasis. About 20% of patients present visible
metastases with imaging at diagnosis and a quarter pa-
tients have metastases during the course of treatment
[2]. However, due to lack of effective and efficient tumor
biomarkers for early diagnosis, and that any treatment
for relapse is absolutely resistant to the relapsed tumor,
the prognosis remains poor and most patients die at the
advanced stages. Thus, developing a novel predictor for
anticipating the invasive potential and prognosis of
osteosarcoma is significantly crucial.* Correspondence: anhuishenghufei@163.com
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unless otherwise stated.Periostin (PN), a member of the fasciclin domain and also
called osteoblast-specific factor 2 (OSF-2), is a disulfide-
linked cell adhesion protein that has been shown to be
expressed preferentially in the periosteum and periodontal
ligaments, acting as a critical regulator for bone and tooth
formation and maintenance [3-6]. Recently, accumulating
evidence has revealed that PN is overexpressed in various
human cancers including liver, head and neck, neuroblast-
oma, breast, colon, esophageal, ovary, and so on [7-17].
Furthermore, PN as a promising marker for tumor ag-
gression in different types of human cancer have been
identified [8,10]. In the past, although many studies have
focused on the multiple facets of PN in bone metabolism
[18-23], few were reported about the expression of PN in
bone-related tumors and its potential clinical significance.
In the present study, we have examined the expression
levels of PN in osteosarcoma and analyzed its correlation
with clinicopathological characteristics and prognosis.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Patients and tissue samples
A total of 124 patients (62 cases with osteosarcoma and
62 with osteochondroma) who underwent surgical resec-
tion between 2003 and 2010 were selected from the De-
partment of Orthopedics in Anhui Provincial Hospital
(China). These patients with osteosarcoma were treated
according to the standardized protocol consisting of neo-
adjuvant chemotherapy (four cycles of methotrexate and
cisplatin were administered with a minimum of a 21-day
interval between consecutive cycles), followed by appro-
priate surgical management and postoperative adjuvant
chemotherapy. All tissue specimens were formalin-fixed
and paraffin-embedded for immunohistochemistry stain-
ing. Detailed pathological and clinical data were collected
by reviewing medical records, including age and gender, age
at diagnosis, tumor size, site of primary disease, histologic
subtype, complete blood count, erythrocyte sedimentationFigure 1 Immunohistochemical staining of periostin in osteosarcoma
cytoplasm of osteosarcoma tissues. (A) H&E staining of osteosarcoma, ×100
staining in osteosarcoma, ×400; (D) negative for PN staining in osteosarcom
staining in osteosarcoma, ×100.rate, alkaline phosphatase, serum albumin, and Enneking
stage. A total of 62 patients with osteosarcoma were com-
prised of 33 males and 29 females, with the mean age of
25 ± 12-years-old (range: 6 to 52 years). Two pathologists
who were blinded to the clinical information confirmed all
histological diagnoses and judged the degree of staining
independently.
All patients involved in this study had signed the in-
formed consent. The study protocol conformed to the
ethical guidelines of the Declaration of Helsinki. Ethical
approval for the use of human subjects was obtained
from the research ethics committee of Anhui Medical
University.
Follow-up was terminated on 8 August 2013. The mean
follow-up was of 36.6 months (range: 25 to 92 months).
After surgical resection, all patients were monitored using
X-ray as preferential, abdominal ultrasonography, techne-
tium bone scans, chest computed tomography (CT) scansand osteochondroma tissues. Periostin (PN) mainly expressed in the
; (B) negative for PN staining in osteochondroma, ×100; (C) ++ for PN
a, ×40; (E) + for PN staining in osteosarcoma, ×100; (F) ++ for PN
Table 1 Differential expression of periostin between






Osteosarcoma 62 50 12 80.6%
Osteochondroma 62 11 51 17.7%
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three to six months, prospectively. Overall survival (OS)
was defined as the interval between surgery and death
or the last observation taken. The data were censored at






Male 33 26 7
Female 29 24 5
Age at diagnosis (years)
<30 42 34 8
>30 20 16 4
Site of primary disease
Tibia 26 22 4
Femur 16 13 3
Humerus 10 7 3
Other 10 8 2
Histologic subtype
Special 5 0 5
conventional 57 50 7
Enneking stage
I, II 49 37 12
III 13 13 0
Size (at diagnosis) (cm)
<5 38 27 11
>5 24 23 1
Alkaline phosphatase (u/L)
<500 35 28 7
>500 27 22 5
Serum albumin (g/L)
<30 22 18 4
>30 40 32 8
ESR (mm/hr)
<30 45 36 9
>30 17 14 3
CI: Confidence interval; ESR: erythrocyte sedimentation rate; OR: the odds ratio; PN:
P <0.05 was considered to be statistically significant.survival (RFS) was defined as the interval between the date
of surgery and the date of diagnosis of any type of relapse
or the last follow-up assessment.
Histopathological and immunohistochemical analyses
Immunohistochemistry was used to examine the expression
of PN in all tissue specimens. Rabbit anti-periostin antibody
was ordered from Beijing Biosynthesis Biotechnology Co.,
Ltd (Beijing, China). PV-6000 Power Vision ™ Two-step his-
tostaining reagent, 3,3-diaminobenzidine tetrahydrochloride
(DAB) and phosphate-buffered saline (PBS) were obtained
from Beijing Zhongshan Golden Bridge Biotechnology
Company (Beijing, China). The whole process was followed
by the manufacturer’s instructions. Briefly, the tumoropathologic features in 62 osteosarcoma patients (cases)
χ2 P value OR 95% CI
ive
0.156 0.693 0.774 0.216 ~ 2.768
0.008 0.929 0.941 0.247 ~ 3.592
0.995 0.802
22.661 0.000 8.143 4.069 ~ 16.297
3.948 0.047 1.324 1.129 ~ 1.553
5.787 0.016 9.370 1.123 ~ 78.169
0.021 0.884 0.909 0.254 ~ 3.258
0.03 0.862 0.889 0.235 ~ 3.367
0.044 0.834 0.857 0.202 ~ 3.636
Periostin.
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and cut into 4-μm-thick sections. The sections were
stained with hematoxylin and eosin (HE) for histological
examination. The tissue sections were deparaffinized and
rehydrated in a graded series of alcohols. The sections
were microwaved in citrate buffer (pH 6.0) for 20 minutes
and then cooled for an additional 20 minutes at room
temperature. Endogenous peroxidase activity was blocked
with 3% hydrogen peroxide for 10 minutes. The sec-
tions were then immunostained with PN antibody (1:50)
(Zhongshan Jinqiao Co., Beijing, China) and incubated at
4°C overnight. After rinsing with PBS three times for 5 mi-
nutes each, the sections were incubated in horseradish
peroxidase-conjugated secondary antibody (Zhongshan
Jinqiao Co., Beijing, China) for 20 minutes. After being
washed again, peroxidase activity was visualized with
DAB as a chromogen. Sections were counterstained with
hematoxylin, dehydrated and mounted. The negative con-
trols were processed in a similar manner with PBS instead
of primary antibody. The result of immunohistochemistry
was expressed by the staining cells on a graduated per-
centage (0 to 100%). Staining of under 10% of the tumor
cells showed weak or focal immunopositivity or no stain-
ing was clarified as negative., staining of 10 to 30% of
tumor cells showed moderate or patchy immunopositivity
as +, and staining of over 30% of tumor cells showed
strong or diffuse immunopositivity as ++. A total of 10
fields were selected, and expression in 1,000 tumor cellsFigure 2 Kaplan-Meier analysis of overall survival (OS) and disease-fre
periostin expression as positive or negative. (A) OS curve of patients w
patients with osteosarcoma based on periostin expression. The osteosarcom
poorer OS and DFS rates than those with periostin-negative expression.(100 cells/field) was evaluated using a high-power (400×)
microscope [9].
Statistical analysis
All statistical analyses were performed using SPSS 13.0
(SPSS Inc., Chicago, Illinois, United States). χ2 and Fisher’s
exact test was performed to assess associations between
PN expression and clinicopathological parameters. The
Kaplan-Meier method was used for survival analysis, and
differences in survival were estimated using the log-rank
test. A multivariate survival analysis was performed for all
parameters that were significant in the univariate analysis
using the Cox regression model. P <0.05 was considered
to be statistically significant.
Results
Immunohistochemical expression of periostin in
osteosarcoma and osteochondroma
Immunohistochemical analysis revealed that the positive
expression of PN was mainly localized in the cytoplasm,
with some tumor cells stained strongly, while others ex-
hibited little or no staining at all (Figure 1). The positive
rates of PN in osteosarcoma tissues were 80.6% (50 out of
62) and 17.7% in osteochondroma (11 out of 62), and PN
expression in osteochondroma was significantly lower
than that in osteosarcoma tissues (Table 1, P <0.05).
To elucidate its clinical significance we evaluated the as-
sociation between PN expression and clinicopathologicale survival (DFS) curves of patients with osteosarcoma based on
ith osteosarcoma based on periostin expression; (B) DFS curve of
a patients with periostin-positive expression showed significantly
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subtype, tumor size, Enneking stage, alkaline phosphatase,
serum albumin and erythrocyte sedimentation rate (ESR).
A detailed histological subtype showed 57 cases of con-
ventional osteosarcoma, 5 cases of special osteosarcoma
(including 4 cases of low-grade central osteosarcoma) and
1 case of parosteal osteosarcoma. As shown in Table 2,
the expression level of PN was associated with pathologic
subtype (P = 0.000, odds ratio (OR) = 8.143), tumor size
(P = 0.016, OR = 9.370) and Enneking stage (P = 0.047,Table 3 Univariate analysis of factors associated with OS and
Variable OS







Age at diagnosis (years)
<30 35 30.480-39.391
>30 31 25.388-36.612









I, II 40 35.700-44.668
III 15 10.727-19.580
Size (at diagnosis) (cm)
< 5 44 39.965-49.193
> 5 19 15.395-23.938
Alkaline phosphatase (u/L)
< 500 33 30.480-38.391
> 500 31 25.388-36.612
Serum albumin (g/L)
< 30 35 31.224-39.031
> 30 31 25.308-35.578
ESR (mm/hr)
< 30 34 31.135-39.023
> 30 31 25.886-34.479
CI: Confidence interval; DFS: disease free survival; ESR: erythrocyte sedimentation ra
P <0.05 was considered to be statistically significant.OR= 1.324), but there was no significant correlation with
age, gender, location, alkaline phosphatase level, serum al-
bumin level and ESR.
Relationship between PN expression and prognosis in
osteosarcoma
Patients with PN-positive expression showed a poorer
prognosis than those with PN-negative expression by the
Kaplan-Meier analysis. The log-rank test revealed that the
overall survival time of osteosarcoma patients with PN-DFS
DFS
P value Mean survival month 95% CI P value
0.003 42 32.503-50.663 0.001
23 19.578-29.222
0.073 26 22.971-30.868 0.066
23 16.055-29.945
0.169 26 22.971-30.868 0.169
23 16.055-29.945




0.000 56 46.412-65.988 0.000
24 20.849-27.852
0.000 31 27.668-35.556 0.000
9 5.144-13.318
0.000 35 31.469-39.636 0.000
13 9.586-16.914
0.162 26 22.971-30.868 0.151
23 16.055-29.945
0.211 27 22.845-31.547 0.278
24 18.454-28.567
0.060 26 21.975-30.086 0.126
23 19.333-28.792
te; OS: Overall survival;
Figure 3 Kaplan-Meier analysis of overall survival (OS) and disease-free survival (DFS) curves of patients with osteosarcoma based on
periostin expression as strongly positive, weakly positive or negative. (A) OS curve of patients with osteosarcoma based on periostin
expression; (B) DFS curve of patients with osteosarcoma based on periostin expression. The osteosarcoma patients with periostin-positive expression
showed significantly poorer OS and DFS rates than those with periostin-negative expression. The survival of patients in the strongly positive periostin
expression was poorest.
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PN-negative expression (P = 0.003; Figure 2A; Table 3).
Furthermore, similar results were also observed in the
disease-free survival analysis (P = 0.001; Figure 2B; Table 3).
To understand deeply about the relationship between
the PN-positive expression and prognosis, two different
degrees of positive expression were analyzed using the
Kaplan-Meier method (Figure 3). Moreover, as seen in
Table 4, multivariate Cox analysis indicated that PN ex-
pression was one of the independent prognostic factors,
along with pathologic subtype, Enneking stage and tumor
size. At the last follow-up appointment, 44 patients in the
PN-positive groups had died, with a median survival time
of 31 months. Of these, two patients developed local re-
currence and three had lung metastasis. Comparatively,
six patients died in the PN-negative groups and the me-
dian survival time was 51 months.Table 4 Multivariate analysis of factors associated with OS an
Variable O
Hazard ratio 9
Periostin (Negative versus positive) 3.751 1.5
Pathologic subtype (Conventional versus special) 2.434 1.2
Enneking stage (I, II versus III) 3.156 1.7
Tumor size, cm (≤5 versus >5) 2.039 1.1
CI: Confidence interval; DFS: disease free survival; OS: Overall survival. P <0.05 was cDiscussion
Periostin, originally named as osteoblast-specific factor-2
(OSF-2) and first identified in bone, has been implicated
in regulating adhesion and differentiation of osteoblasts
[3-5]. The molecular structure of PN is particularly
highly homologous to ßig-h3, which promotes cell adhe-
sion and the spreading of fibroblasts [3]. By RNA dot-blot
analysis, PN expression was observed in a wide range of
normal adult tissues, including aorta, stomach, lower
gastrointestinal tract, placenta, uterus and breast [24]. Re-
cently, it has been frequently reported that PN is overex-
pressed in various types of human malignant tumors. For
instance, Kudo et al. [9] reported PN was overexpressed
in oral cancer cells and enhanced migration and invasion.
Furthermore, in vitro studies such as Bao et al. [14], dem-
onstrated that highly vascular metastatic tumors derived
from the periostin-producing cells showed fewer apoptoticd DFS
S DFS
5% CI P value Hazard ratio 95% CI P value
64-8.367 0.001 3.403 1.644-7.908 0.001
75-4.564 0.003 2.822 1.577-5.057 0.001
88-5.693 0.000 3.172 1.809-5.629 0.000
08-3.784 0.021 2.024 1.137-3.70 0.018
onsidered statistically significant.
Hu et al. World Journal of Surgical Oncology 2014, 12:287 Page 7 of 8
http://www.wjso.com/content/12/1/287cells than control cells. Accumulated findings indicated
that overexpression of PN might be common in tumor de-
velopment. However, some authors have reported that
downregulation of PN mRNA was significantly related to
higher grade bladder cancer [25,26]. Furthermore, Kanno
et al. [27] have demonstrated that PN has biphasic effects
on the migration of pancreatic carcinoma. These varied
findings suggest that PN might have different functions
for different pathological types of cancer. However, PN ex-
pression status and the relation with prognosis in osteo-
sarcoma have not been clearly explained until now.
Osteosarcoma is the most common malignant primary
bone tumor with a high capacity for distant metastasis.
Although the survival rate for patients with osteosar-
coma has significantly improved over the past two de-
cades through the use of a combination of aggressive
chemotherapy and surgery, metastatic or recurrent disease
still occurs in 30 to 40% of these patients and the majority
of those succumb to the disease [28]. Therefore, it is crit-
ical to identify the tumor metastasis-associated biomarkers
of osteosarcoma. In the present study, we discovered that
the PN expression in tumor tissues of patients with osteo-
sarcoma was significantly increased compared with those
with osteochondroma. Furthermore, we found that osteo-
sarcoma with PN-positive expression were more frequently
Enneking stage III, with a tumor size >5 cm, and a conven-
tional pathologic subtype than osteosarcoma with PN-
negative expression. Accumulated findings indicated that
OS and DFS were better in patients without PN expression
than those in patients with PN-positive expression. Both
Kaplan-Meier and multivariate analysis showed that the
expression of PN was an independent predictor of poor
prognosis for both OS and DFS. The relationship between
PN staining intensity and patient survival was also ana-
lyzed, and a general inverse trend between a decline in pa-
tient survival and an increase in PN staining intensity was
observed. As observed in other cancers, increased expres-
sion of PN was associated with cell proliferation, adhesion,
and migration. These results indicated that PN expression
had an adverse influence on the osteosarcoma outcome.
PN may be used as a marker to predict osteosarcoma pa-
tients’ prognosis.
A major limitation of this single-center study is its rela-
tively small sample size. Secondly, the underlying molecu-
lar mechanisms are not been explored in this study.
Recently, some studies revealed that PN binding to the
integrins activates the focal adhesion kinase (FAK)- and
protein kinase B (Akt/PKB)-mediated signaling pathways
which promote tumor angiogenesis, invasion, and metas-
tasis [29,30]. On the other hand, Windischhofer et al. [31]
demonstrated that PN was abundantly expressed in hu-
man MG-63 osteosarcoma cells. Stimulation of cells with
Lysophosphatidic acid (LPA) resulted in a decrease of PN
that was strictly dependent on early growth response-1(Egr-1) expression levels mediated strictly via the Gαi/
Src/p42/44 MAPK(mitogen-activated protein kinases)
pathway with no involvement of the Gαq/11/PLC/PKC
(phospholipase C, protein kinase C) or the PLD (phospho-
lipase D)/PI3 kinase/Akt pathways. Thus, to illuminate
these findings, further investigations will still be required
to explore its exact mechanisms.
Conclusions
In conclusion, our study found that PN expression was
higher in osteosarcoma tissues compared with osteochon-
droma tissues and its overexpression was closely correlated
with Enneking stage, tumor size, and pathologic subtype.
Taken together, these preliminary results suggest that the
overexpression of PN is a potential prognostic factor for
osteosarcoma development and progression. In future,
if this activity could be blocked by some specific in-
hibitors, it could provide a new target for the treatment
of osteosarcoma.
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